Gene · 4481
Papers3,855
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,855
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The nucleolar phase of signal recognition particle assembly. | Life Sci Alliance | 2024 | 38858088 | PubTator, text mining | PubMed |
| Seeing Beyond the Surface: Superior Performance of Ultrasound Elastography over Milan Ultrasound Criteria in Distinguishing Fibrosis of Ulcerative Colitis. | J Crohns Colitis | 2024 | 38828738 | PubTator, text mining | PubMed |
| Pathways for macrophage uptake of cell-free circular RNAs. | Mol Cell | 2024 | 38761795 | PubTator, text mining | PubMed |
| T-reg transcriptomic signatures identify response to check-point inhibitors. | Sci Rep | 2024 | 38710724 | PubTator, text mining | PubMed |
| Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma. | Cancer Sci | 2024 | 38693726 | PubTator, text mining | PubMed |
| In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies. | Int J Mol Sci | 2024 | 38612803 | PubTator, text mining | PubMed |
| Recombinant human proteoglycan 4 lowers inflammation and atherosclerosis susceptibility in female low-density lipoprotein receptor knockout mice. | J Physiol | 2024 | 38606903 | PubTator, text mining | PubMed |
| A multiscale modeling study of nanoparticle-based targeting therapy against atherosclerosis. | J Biomech | 2024 | 38556387 | PubTator, text mining | PubMed |
| Histiocytic Sarcoma in a Captive Hybrid Orangutan (Pongo sp.): Morphological and Immunohistochemical Features. | Animals (Basel) | 2024 | 38539950 | PubTator, text mining | PubMed |
Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. | Cancers (Basel) | 2024 | 38539537 | PubTator, text mining | PubMed |
| Genomic and clinical characterization of a familial GIST kindred intolerant to imatinib. | NPJ Genom Med | 2024 | 38538628 | PubTator, text mining | PubMed |
| Beyond Traditional Medicine: EVs-Loaded Hydrogels as a Game Changer in Disease Therapeutics. | Gels | 2024 | 38534580 | PubTator, text mining | PubMed |
| Comprehensive analyses of m1A regulator-mediated modification patterns determining prognosis in lower-grade glioma (running title: m1A in LGG). | Heliyon | 2024 | 38510043 | PubTator, text mining | PubMed |
| Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease. | Arthritis Res Ther | 2024 | 38509595 | PubTator, text mining | PubMed |
| Prognostic and clinical significance of tumor-associated macrophages in esophageal squamous cell carcinoma after surgery: do biomarkers and distributions matter? | Biosci Rep | 2024 | 38501293 | PubTator, text mining | PubMed |
| Macrophage immunophenotypes in Jorge Lobo's disease and lepromatous leprosy- A comparative study. | Microb Pathog | 2024 | 38484920 | PubTator, text mining | PubMed |
| High CD204+ tumor-associated macrophage density predicts a poor prognosis in patients with clear cell renal cell carcinoma. | J Cancer | 2024 | 38370385 | PubTator, text mining | PubMed |
| Effects of the Cortisol Milieu on Tumor-Infiltrating Immune Cells in Corticotroph Tumors. | Endocrinology | 2024 | 38340329 | PubTator, text mining | PubMed |
| Downregulation of LILRB4 Promotes Human Aortic Smooth Muscle Cell Contractile Phenotypic Switch and Apoptosis in Aortic Dissection. | Cardiovasc Toxicol | 2024 | 38324114 | PubTator, text mining | PubMed |
| Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma. | Eur Urol Oncol | 2024 | 38320909 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4481/papers?page=10